爱尔兰爵士制药的去纤维钠去哪买的到？

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. It is a mixture of single-stranded oligonucleotides with anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide sodium is a safe and effective drug for preventing and treating HVOD after HSCT. Defibrotide sodium was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defibrotide sodium was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States on March 30, 2016, under the trade name Defitelio.

In vitro, defibrinated sodium enhances the enzymatic activity of plasmin that hydrolyzes fibrin clots. Studies evaluating the pharmacological effects of defibrinated sodium on endothelial cells (ECs) have been primarily conducted in human microvascular endothelial cell lines. In vitro, defibrotide increases tissue plasminogen activator (t-PA) and thrombomodulin expression and decreases von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression, thereby reducing EC activation and increasing EC-mediated fibrinolysis. Defibrinated sodium protects ECs from chemotherapy, tumor necrosis factor-alpha (TNF-alpha), serum starvation, and perfusion-induced injury.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) was founded in 2003 and is headquartered in Dublin, Ireland. It has 1,620 full-time employees. It is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Irish Jazz Pharmaceuticals' defibrinated sodium is not on the domestic market. Patients in need of medicine can obtain genuine products listed overseas through domestic professional overseas medical service organizations, such as Medical Companion Travel.

Recommended related hot articles: /newsDetail/95919.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.